Telix 1H 2022 Financial Results and Company Update Investor Call
Telix advises that it will release financial results for the half-year ending 30 June 2022 on Thursday 18 August 2022.
APAC Report: Regulatory Progress for Prostate and Kidney Cancer Imaging
Telix today reports on regulatory progress for the Company’s core prostate and kidney cancer imaging programs in the Asia Pacific (APAC) Operating Region, including progress in the major market of China with its strategic partner Grand Pharmaceutical Group Limited (Grand Pharma).
Activities Report and Appendix 4C for June 2022 Quarter
Telix issues Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 30 June 2022.
ZIRCON Phase III Kidney Cancer Imaging Study Completes Enrolment
Telix Announces a Final Patient Dosed and Recruitment Completed into the Phase III Pivotal ZIRCON Study of TLX250-CDx for Kidney Cancer Imaging
Chief Medical Officer, Dr. Colin Hayward, Discussion with Wilsons Advisory
Telix Chief Medical Officer, Dr. Colin Hayward, was hosted this week by Shane Storey, Senior Research Analyst at Wilsons Advisory and Stockbroking Limited, to discuss R&D insights across Telix’s imaging and therapeutic research pipeline.
Telix AGM 2022
Telix's 2022 AGM was held on Wednesday, 18th May 2022 at The Events Centre in Melbourne, Australia.
Telix Further Strengthens European Distribution Network for Illuccix
Telix announces agreements with Avanço and THP for the distribution of Telix’s prostate cancer investigational imaging product for the Portuguese and Austrian, Czech Republic and Slovak Republic markets.
Activities Report and Appendix 4C for March 2022 Quarter
Telix issues Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 31 March 2022
First Patients Dosed with Illuccix® – Telix’s Approved Prostate Cancer Imaging Agent
Telix announces the first commercial doses of its prostate cancer imaging agent, Illuccix®
Notice of Annual General Meeting 2022
Telix provides notice of The Annual General Meeting of Shareholders on Wednesday 18 May 2022